Literature DB >> 24745672

Molecular defects in mastocytosis: KIT and beyond KIT.

Siham Bibi1, Florent Langenfeld1, Sylvie Jeanningros1, Fabienne Brenet2, Erinn Soucie2, Olivier Hermine3, Gandhi Damaj4, Patrice Dubreuil5, Michel Arock6.   

Abstract

In all variants of mastocytosis, activating KIT mutations are frequently found. In adults, neoplastic mast cells (MCs) cells show the KIT mutation D816V, whereas in children, MCs invading the skin are frequently positive for non-KIT D816V mutations. The clinical course and prognosis of the disease vary among patients with systemic mastocytosis (SM). Additional KIT-independent molecular defects might cause progression. Additional oncogenic lesions have recently been identified in advanced SM. In advanced SM the presence of additional genetic lesions or altered signaling worsening the prognosis might lead to the use of alternative therapies such as combined antisignaling targeted treatments or stem cell transplantation.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ASXL1; KIT; Mutation; Signaling; Spliceosome; Systemic mastocytosis; TET2; Targeted therapy

Mesh:

Substances:

Year:  2014        PMID: 24745672     DOI: 10.1016/j.iac.2014.01.009

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  25 in total

1.  Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.

Authors:  M Jawhar; J Schwaab; S Schnittger; K Sotlar; H-P Horny; G Metzgeroth; N Müller; S Schneider; N Naumann; C Walz; T Haferlach; P Valent; W-K Hofmann; N C P Cross; A Fabarius; A Reiter
Journal:  Leukemia       Date:  2015-01-08       Impact factor: 11.528

2.  A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.

Authors:  Jason Gotlib; John H Baird; Tracy I George; Cheryl Langford; Isabel Reyes; Justin Abuel; Cecelia Perkins; Kurt Schroeder; Prithviraj Bose; Srdan Verstovsek
Journal:  Blood Adv       Date:  2019-08-13

Review 3.  Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.

Authors:  Peter Valent; Cem Akin; Karin Hartmann; Gunnar Nilsson; Andreas Reiter; Olivier Hermine; Karl Sotlar; Wolfgang R Sperr; Luis Escribano; Tracy I George; Hanneke C Kluin-Nelemans; Celalettin Ustun; Massimo Triggiani; Knut Brockow; Jason Gotlib; Alberto Orfao; Lawrence B Schwartz; Sigurd Broesby-Olsen; Carsten Bindslev-Jensen; Petri T Kovanen; Stephen J Galli; K Frank Austen; Daniel A Arber; Hans-Peter Horny; Michel Arock; Dean D Metcalfe
Journal:  Cancer Res       Date:  2017-03-02       Impact factor: 12.701

4.  Oxidative Stress in Children with Cutaneous Mastocytosis.

Authors:  Aysegul Ertugrul; Ilknur Bostanci; Ozcan Erel
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2020-04-28       Impact factor: 0.885

Review 5.  Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.

Authors:  Molly M Gallogly; Hillard M Lazarus; Brenda W Cooper
Journal:  Ther Adv Hematol       Date:  2017-08-19

6.  Impact of somatic and germline mutations on the outcome of systemic mastocytosis.

Authors:  Javier I Muñoz-González; María Jara-Acevedo; Iván Alvarez-Twose; Jason D Merker; Cristina Teodosio; Yanli Hou; Ana Henriques; Krishna M Roskin; Laura Sanchez-Muñoz; Albert G Tsai; Carolina Caldas; Almudena Matito; J Ignacio Sánchez-Gallego; Andrea Mayado; Noelia Dasilva-Freire; Jason R Gotlib; Luis Escribano; Alberto Orfao; Andrés C García-Montero
Journal:  Blood Adv       Date:  2018-11-13

7.  Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis.

Authors:  Jeffrey W Craig; Robert P Hasserjian; Annette S Kim; Jon C Aster; Geraldine S Pinkus; Jason L Hornick; David P Steensma; R Coleman Lindsley; Daniel J DeAngelo; Elizabeth A Morgan
Journal:  Mod Pathol       Date:  2020-01-02       Impact factor: 7.842

Review 8.  KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis.

Authors:  M Arock; K Sotlar; C Akin; S Broesby-Olsen; G Hoermann; L Escribano; T K Kristensen; H C Kluin-Nelemans; O Hermine; P Dubreuil; W R Sperr; K Hartmann; J Gotlib; N C P Cross; T Haferlach; A Garcia-Montero; A Orfao; J Schwaab; M Triggiani; H-P Horny; D D Metcalfe; A Reiter; P Valent
Journal:  Leukemia       Date:  2015-02-04       Impact factor: 11.528

Review 9.  Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features.

Authors:  Peter Valent; Karl Sotlar; Wolfgang R Sperr; Andreas Reiter; Michel Arock; Hans-Peter Horny
Journal:  Leuk Res       Date:  2014-09-30       Impact factor: 3.156

10.  TET2 regulates immune tolerance in chronically activated mast cells.

Authors:  Riccardo Rigo; Rabie Chelbi; Julie Agopian; Sebastien Letard; Aurélien Griffon; Hussein Ghamlouch; Julien Vernerey; Vasileios Ladopoulos; Edwige Voisset; Paulo De Sepulveda; Geoffrey Guittard; Jacques A Nunès; Ghislain Bidaut; Berthold Göttgens; Michael Weber; Olivier A Bernard; Patrice Dubreuil; Erinn Soucie
Journal:  JCI Insight       Date:  2022-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.